Aldeyra Therapeutics Entered into an Agreement with AbbVie for Reproxalap to Treat Dry Eye Disease
Shots:
- Under the terms of the agreement, Aldeyra granted AbbVie an option to acquire a co-exclusive license & exclusive license to develop, manufacture & commercialize reproxalap across the US & ROW respectively
- In return, Aldeyra will receive a non-refundable option fee worth $1M, an up front payment of $100M less option fee if exercised by AbbVie & is also eligible to receive up to $200M as commercial milestones & $100M as a regulatory milestone, plus tiered royalties on net sales of reproxalap across the US
- Following the commercialization of reproxalap, AbbVie and Aldeyra will split the profits gained and losses faced as 60% and 40% respectively
Ref: Businesswire | Image: Aldeyra Therapeutics
Related News:- Aldeyra Therapeutics Reports the US FDA Acceptance of NDA for Reproxalap to Treat Dry Eye Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
